MA33974B1 - Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek - Google Patents

Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Info

Publication number
MA33974B1
MA33974B1 MA34821A MA34821A MA33974B1 MA 33974 B1 MA33974 B1 MA 33974B1 MA 34821 A MA34821 A MA 34821A MA 34821 A MA34821 A MA 34821A MA 33974 B1 MA33974 B1 MA 33974B1
Authority
MA
Morocco
Prior art keywords
inhibitor
combinations
pi3k
mek
kinase inhibitor
Prior art date
Application number
MA34821A
Other languages
Arabic (ar)
English (en)
Inventor
Marcia Belvin
Iris T Chan
Lori Friedman
Klause P Hoeflich
John Prescott
Jeffrey Wallin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33974B1 publication Critical patent/MA33974B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des procédés de traitement d'un patient présentant des tumeurs solides localement avancées ou métastasiques par une combinaison d'un inhibiteur de phosphatidylinositol 3-kinase (pi 3-kinase ou pi3k) et un inhibiteur de kinase de kinase de protéine activée par le mitogène.
MA34821A 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek MA33974B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Publications (1)

Publication Number Publication Date
MA33974B1 true MA33974B1 (fr) 2013-02-01

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34821A MA33974B1 (fr) 2009-10-12 2010-10-11 Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek

Country Status (24)

Country Link
US (1) US20110086837A1 (fr)
EP (1) EP2488178B1 (fr)
JP (2) JP2013507415A (fr)
KR (1) KR101489045B1 (fr)
CN (1) CN102740851B (fr)
AR (1) AR078588A1 (fr)
AU (1) AU2010314287A1 (fr)
BR (1) BR112012008483A2 (fr)
CA (1) CA2776944A1 (fr)
CL (1) CL2012000913A1 (fr)
CO (1) CO6531463A2 (fr)
CR (1) CR20120173A (fr)
EC (1) ECSP12011865A (fr)
ES (1) ES2609767T3 (fr)
IL (1) IL219105A0 (fr)
MA (1) MA33974B1 (fr)
MX (1) MX345155B (fr)
NZ (1) NZ599939A (fr)
PE (1) PE20121816A1 (fr)
PH (1) PH12012500709A1 (fr)
RU (1) RU2563193C2 (fr)
TW (1) TWI428336B (fr)
WO (1) WO2011054620A1 (fr)
ZA (1) ZA201202618B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (fr) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Dérivés de triazolo[4,3-b]pyridazines au cycle 6,7 fusionné utilisés en tant qu'inhibiteurs de pim
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2849331A1 (fr) 2011-10-13 2013-04-18 Genentech, Inc. Traitement de l'hypochlorhydrie induite pharmacologiquement
PE20142312A1 (es) * 2011-10-28 2015-01-25 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
AU2013243429A1 (en) * 2012-04-06 2014-10-23 Merck Patent Gmbh Methods for treating cancer using PI3K inhibitor and MEK inhibitor
EP2851078B1 (fr) * 2012-04-19 2017-06-07 Kyushu University, National University Corporation Composition pharmaceutique
WO2013182668A1 (fr) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Sélectivité mutante et associations d'un inhibiteur de phospho‑inositide 3 kinase et agents chimiothérapeutiques pour le traitement du cancer
CA2879665A1 (fr) 2012-08-02 2014-02-06 Genentech, Inc. Anticorps et immunoconjugues anti-etbr
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016040806A1 (fr) * 2014-09-11 2016-03-17 The Regents Of The University Of California Inhibiteurs de mtorc1
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (fr) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (fr) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
CA2186947A1 (fr) * 1994-04-01 1995-10-12 Kazuo Ueda Derive d'oxime et bactericide le contenant en tant qu'ingredient actif
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2517517C (fr) * 2003-03-03 2012-12-18 Array Biopharma, Inc. Inhibiteurs de la p 38 et leurs procedes d'utilisation
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
WO2008070740A1 (fr) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Composés inhibant la phosphoinositide 3 kinase et procédés d'utilisation
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Also Published As

Publication number Publication date
BR112012008483A2 (pt) 2019-09-24
CO6531463A2 (es) 2012-09-28
CA2776944A1 (fr) 2011-05-12
JP5745678B2 (ja) 2015-07-08
WO2011054620A1 (fr) 2011-05-12
AR078588A1 (es) 2011-11-16
CN102740851A (zh) 2012-10-17
ES2609767T3 (es) 2017-04-24
AU2010314287A1 (en) 2012-05-03
PE20121816A1 (es) 2013-01-02
EP2488178A1 (fr) 2012-08-22
PH12012500709A1 (en) 2012-10-29
KR101489045B1 (ko) 2015-02-02
AU2010314287A2 (en) 2012-07-12
KR20120064132A (ko) 2012-06-18
JP2013507415A (ja) 2013-03-04
ECSP12011865A (es) 2012-06-29
CR20120173A (es) 2012-07-04
TWI428336B (zh) 2014-03-01
TW201118082A (en) 2011-06-01
CN102740851B (zh) 2013-12-18
RU2012118974A (ru) 2013-11-20
MX345155B (es) 2017-01-18
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
CL2012000913A1 (es) 2012-09-14
US20110086837A1 (en) 2011-04-14
IL219105A0 (en) 2012-06-28
NZ599939A (en) 2014-02-28
HK1175125A1 (en) 2013-06-28
JP2015038110A (ja) 2015-02-26
ZA201202618B (en) 2014-10-29
EP2488178B1 (fr) 2016-11-16

Similar Documents

Publication Publication Date Title
MA33974B1 (fr) Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
DE502007002289D1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
MX2009011226A (es) Inhibidores especificos pdgfrbeta.
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
NZ588033A (en) Methods of treating a mif-mediated disorder
MX2010003013A (es) Inhibicion de angiogenesis.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
CR20120653A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
BR112014004577A2 (pt) inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.